← 返回

一种用于胰腺癌局部消融和免疫激活的离子液体消融剂

英文原题:An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer.

查看英文原题

An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer.

PubMed 2023/01/25(内容时间) Adv Sci (Weinh) Q1 · IF 14.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺导管腺癌迅速对化疗产生耐药性,仍是一种致命性疾病。免疫治疗是癌症治疗的突破之一,包括免疫检查点抑制剂、CAR-T 细胞免疫治疗和新抗原疫苗。然而,免疫治疗在胰腺癌治疗中尚未取得令人满意的结果。免疫原性死亡包括促炎性细胞死亡,为增强肿瘤免疫原性并促进实体瘤中的免疫反应提供了一种途径。本文描述了一种由胆碱和香叶酸合成的离子液体消融剂(LAA),通过将免疫抑制性“冷”肿瘤重塑为免疫激活的“热”肿瘤,触发坏死诱导的免疫治疗。结果表明,LAA处理的肿瘤细胞可以增强免疫原性,诱导树突状细胞成熟、巨噬细胞M1极化和细胞毒性T淋巴细胞浸润。本研究结果为实体瘤免疫治疗提供了一种新策略。

展开英文摘要原文

Pancreatic ductal adenocarcinoma rapidly acquires resistance to chemotherapy, remaining a fatal disease. Immunotherapy is one of the breakthroughs in cancer treatment, which includes immune checkpoint inhibitors, chimeric antigen receptor T-cell immunotherapy, and neoantigen vaccines.

However, immunotherapy has not achieved satisfactory results in the treatment of pancreatic cancer. Immunogenic death comprises proinflammatory cell death, which provides a way to enhance tumor immunogenicity and promote an immune response in solid tumors.

Herein, an ionic liquid ablation agent (LAA), synthesized from choline and geranic acid, which triggers necrosis-induced immunotherapy by remodeling an immunosuppressive "cold" tumor to an immune activated "hot" tumor is described. The results indicate that LAA-treated tumor cells can enhance immunogenicity, inducing dendritic cell maturation, macrophage M1 polarization, and cytotoxic T lymphocyte infiltration. The results of the present study provide a novel strategy for solid tumor immunotherapy.

论文信息

作者
Huang J、Wang M、Zhang F、Shao S、Yao Z、Zhao X、Hu Q、Liang T
单位
Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, P. R. China.China
文献类型
非美国政府资助研究
期刊
Advanced science (Weinheim, Baden-Wurttemberg, Germany)2023 Apr
原文标识
PubMed 36698308 · DOI 10.1002/advs.202206756